Sellas Life Sciences has achieved the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to measure the drug's efficacy, with preliminary results expected this quarter. Analysts warn that prolonged trial durations may enhance the likelihood of failure. The company continues to follow the trial's progress closely, with updates anticipated as the trial continues. The REGAL trial is a significant step in the development of Galinpepimut-S, which has shown promising results in previous phases. Sellas Life Sciences remains dedicated on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's careful approach to clinical trials and data analysis is greatly regarded in the industry, and investors are following the trial's outcome with care.